Phase 2
Completed N=59
Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
Premature Atrial Contraction
Source: ClinicalTrials.gov NCT02837328 ↗
Enrolled (actual)
59
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcomePrimary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour
Summary
The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Premature Atrial Contractions (PACs) |
-0.6; -5.6 | — |
| SECONDARY Change in Magnesium Concentration |
0.07; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Age 55 and older
- Ability to speak English
- Availability to attend baseline and follow-up visit approximately 12 weeks after baseline
Exclusion Criteria
- Prior history of heart disease (coronary heart disease, heart failure, atrial fibrillation), stroke, severe renal disease
- Use of type I and III antiarrhythmics or digoxin
- Current use of magnesium supplements
- Any prior history of allergy or intolerance to magnesium
- Prior history of inflammatory bowel disease or any severe gastrointestinal disorder
Data sourced from ClinicalTrials.gov (NCT02837328). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.